VCEL - Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$63.00

52W Low

$33.09

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.34

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

243.21

Forward P/E (<15 better)

131.58

EV/EBITDA (<8 favorable)

105.08

EV/Revenue (<3 favorable)

6.83

P/S (TTM) (<3 favorable)

6.90

P/B (<3 favorable)

5.60

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.06%

Institutions (25–75% balanced)

111.20%

Shares Outstanding

50,460,000

Float

49,903,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

249,119,000

Gross Profit (TTM)

183,038,000

EPS (TTM)

0.14

Profit Margin (>10% good)

0.03%

Operating Margin (TTM) (higher better)

-0.03%

ROE (TTM) (>15% strong)

0.03%

EPS YoY (Quarterly) (>10% good)

0.48

Revenue YoY (Quarterly) (>8% good)

0.20

Momentum

Bearish momentum

Value

-1.5475

-1.4967

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025